Result of a multivariate logistic regression model evaluating HHV-6 as a predictor of delirium while controlling for covariates
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| HHV-6 window* | 2.5 (1.2-5.3) | .02 |
| Age > 30 y | 3.9 (1.6-9.4) | .003 |
| HSV seropositive before transplantation | 2.8 (0.9-8.9) | .08 |
| Medical comorbidity (reference: low) | ||
| Moderate | 1.4 (0.5-4.2) | .57 |
| High | 3.0 (1.1-7.8) | .03 |
| More advanced underlying disease | 2.3 (1.0-4.9) | .04 |
| Conditioning regimen (reference: nonmyeloablative) | ||
| Myeloablative | 5.9 (2.0-17.3) | .001 |
| Reduced intensity | 4.1 (0.7-22.7) | .11 |
| Receipt of acute opioid | 4.2 (2.1-8.4) | < .001 |
| Moderate or severe pain (reference: none or mild) | 1.7 (0.9-3.1) | .12 |
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| HHV-6 window* | 2.5 (1.2-5.3) | .02 |
| Age > 30 y | 3.9 (1.6-9.4) | .003 |
| HSV seropositive before transplantation | 2.8 (0.9-8.9) | .08 |
| Medical comorbidity (reference: low) | ||
| Moderate | 1.4 (0.5-4.2) | .57 |
| High | 3.0 (1.1-7.8) | .03 |
| More advanced underlying disease | 2.3 (1.0-4.9) | .04 |
| Conditioning regimen (reference: nonmyeloablative) | ||
| Myeloablative | 5.9 (2.0-17.3) | .001 |
| Reduced intensity | 4.1 (0.7-22.7) | .11 |
| Receipt of acute opioid | 4.2 (2.1-8.4) | < .001 |
| Moderate or severe pain (reference: none or mild) | 1.7 (0.9-3.1) | .12 |
OR indicates odds ratio; and CI, confidence interval.
Any level of HHV-6 detected up to 2 weeks before or 2 days after first positive delirium assessment within a delirium episode. The interaction term acute HHV-6 underlying disease, P = .10.